Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan E Bates

Showing results (211-220 of 293) with videos related to

Pageof 30
Sort By:
Cancer Reports (Hoboken, N.J.)|February 5, 2022
Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patientsMyles A Ingram, Brianna N Lauren, Yoanna Pumpalova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphomaRichard L Piekarz, A Robin Frye, John J Wright, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2007
Evidence for microtubule target engagement in tumors of patients receiving ixabepiloneSen H Zhuang, Y Elizabeth Hung, Laura Hung, et al.
Pharmacological Reports : PR|November 7, 2006
MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemiaKrzysztof Jamroziak, Ewa Balcerczak, Piotr Smolewski, et al.
Biochimica Et Biophysica Acta|September 13, 2002
Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein MXR/BCRP/ABCP/ABCG2Thomas Litman, Ulla Jensen, Alastair Hansen, et al.
ACS Chemical Biology|June 27, 2009
Botryllamides: natural product inhibitors of ABCG2Curtis J Henrich, Robert W Robey, Kentaro Takada, et al.
Molecular Pharmacology|July 28, 2009
Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug ScreenJohn F Deeken, Robert W Robey, Suneet Shukla, et al.
Epigenomics|November 8, 2012
A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®))Simon J Harrison, Mark Bishton, Susan E Bates, et al.
Haematologica|July 18, 2009
Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series reportDavid Ritchie, Richard L Piekarz, Piers Blombery, et al.
Molecular Oncology|June 24, 2014
Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatinVictoria L Luchenko, Thomas Litman, Arup R Chakraborty, et al.
Pageof 30

Showing results (211-220 of 293) with videos related to

Sort By:
Pageof 30
Cancer Reports (Hoboken, N.J.)|February 5, 2022
Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patientsMyles A Ingram, Brianna N Lauren, Yoanna Pumpalova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphomaRichard L Piekarz, A Robin Frye, John J Wright, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2007
Evidence for microtubule target engagement in tumors of patients receiving ixabepiloneSen H Zhuang, Y Elizabeth Hung, Laura Hung, et al.
Pharmacological Reports : PR|November 7, 2006
MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemiaKrzysztof Jamroziak, Ewa Balcerczak, Piotr Smolewski, et al.
Biochimica Et Biophysica Acta|September 13, 2002
Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein MXR/BCRP/ABCP/ABCG2Thomas Litman, Ulla Jensen, Alastair Hansen, et al.
ACS Chemical Biology|June 27, 2009
Botryllamides: natural product inhibitors of ABCG2Curtis J Henrich, Robert W Robey, Kentaro Takada, et al.
Molecular Pharmacology|July 28, 2009
Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug ScreenJohn F Deeken, Robert W Robey, Suneet Shukla, et al.
Epigenomics|November 8, 2012
A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®))Simon J Harrison, Mark Bishton, Susan E Bates, et al.
Haematologica|July 18, 2009
Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series reportDavid Ritchie, Richard L Piekarz, Piers Blombery, et al.
Molecular Oncology|June 24, 2014
Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatinVictoria L Luchenko, Thomas Litman, Arup R Chakraborty, et al.
Pageof 30